Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Current Leases (2019 - 2020)

Akebia Therapeutics (AKBA) has disclosed Current Leases for 2 consecutive years, with $5.1 million as the latest value for Q1 2020.

  • On a quarterly basis, Current Leases fell 83.72% to $5.1 million in Q1 2020 year-over-year; TTM through Mar 2020 was $5.1 million, a 83.72% decrease, with the full-year FY2019 number at $5.0 million, changed N/A from a year prior.
  • Current Leases was $5.1 million for Q1 2020 at Akebia Therapeutics, up from $5.0 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $31.3 million in Q1 2019 to a low of $4.8 million in Q2 2019.